Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease
- 1 December 2002
- journal article
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 198 (1-2) , 77-87
- https://doi.org/10.1016/s0303-7207(02)00371-4
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancerThe Prostate, 2000
- Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamideProstate Cancer and Prostatic Diseases, 1999
- Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and GoserelinNew England Journal of Medicine, 1997
- Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogensUrology, 1997
- The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 menUrology, 1995
- Long-term Survival and Mortality in Prostate Cancer Treated with Noncurative IntentJournal of Urology, 1995
- Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III eortc trial (30853)Urology, 1993
- Prostate cancer. Primary hormonal treatmentCancer, 1993
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- The Cost of Prostatic Cancer in a Defined PopulationScandinavian Journal of Urology and Nephrology, 1989